Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys

被引:24
作者
Seaman, MS
Santra, S
Newberg, MH
Philippon, V
Manson, K
Xu, L
Gelman, RS
Panicali, D
Mascola, JR
Nabel, GJ
Letvin, NL
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA
[3] Therion Biol, Cambridge, MA USA
[4] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.79.8.4580-4588.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The expression of particular major histocompatibility complex (MHC) class I alleles can influence the rate of disease progression following lentiviral infections. This effect is a presumed consequence of potent cytotoxic T-lymphocyte (CTL) responses that are restricted by these MHC class I molecules. The present studies have examined the impact of the MHC class I allele Mamu-A*01 on simian/human immunodeficiency virus 89.6P (SHIV-89.6P) infection in unvaccinated and vaccinated rhesus monkeys by exploring the contribution of dominant-epitope specific CTL in this setting. Expression of Mamu-A*01 in immunologically naive monkeys was not associated with improved control of viral replication, CD4(+) T-lymphocyte loss, or survival. In contrast, Mamu-A*01(+) monkeys that had received heterologous prime/boost immunizations prior to challenge maintained higher CD4(+) T-lymphocyte levels and better control of SHIV-89.6P replication than Mamu-A*01(-) monkeys. This protection was associated with the evolution of high-frequency anamnestic CTL responses specific for a dominant Mamu-A*01-restricted Gag epitope following infection. These data indicate that specific MHC class I alleles can confer protection in the setting of a pathogenic SHIV infection by their ability to elicit memory CTL following vaccination.
引用
收藏
页码:4580 / 4588
页数:9
相关论文
共 29 条
[1]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[2]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[3]   Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination [J].
Barouch, DH ;
Santra, S ;
Kuroda, MJ ;
Schmitz, JE ;
Plishka, R ;
Buckler-White, A ;
Gaitan, AE ;
Zin, R ;
Nam, JH ;
Wyatt, LS ;
Lifton, MA ;
Nickerson, CE ;
Moss, B ;
Montefiori, DC ;
Hirsch, VM ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2001, 75 (11) :5151-5158
[4]   HLA and HIV-1:: Heterozygote advantage and B*35-Cw*04 disadvantage [J].
Carrington, M ;
Nelson, GW ;
Martin, MP ;
Kissner, T ;
Vlahov, D ;
Goedert, JJ ;
Kaslow, R ;
Buchbinder, S ;
Hoots, K ;
O'Brien, SJ .
SCIENCE, 1999, 283 (5408) :1748-1752
[5]   Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes [J].
Chen, XN ;
Scala, G ;
Quinto, I ;
Liu, WM ;
Chun, TW ;
Justement, JS ;
Cohen, OJ ;
vanCott, TC ;
Iwanicki, M ;
Lewis, MG ;
Greenhouse, J ;
Barry, T ;
Venzon, D ;
Fauci, AS .
NATURE MEDICINE, 2001, 7 (11) :1225-1231
[6]   Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57 [J].
Gillespie, GMA ;
Kaul, R ;
Dong, T ;
Yang, HB ;
Rostron, T ;
Bwayo, JJ ;
Kiama, P ;
Peto, T ;
Plummer, FA ;
McMichael, AJ ;
Rowland-Jones, SL .
AIDS, 2002, 16 (07) :961-972
[7]   HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other [J].
Goulder, PJR ;
Tang, YH ;
Pelton, SI ;
Walker, BD .
JOURNAL OF VIROLOGY, 2000, 74 (11) :5291-5299
[8]   Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection [J].
Kaslow, RA ;
Carrington, M ;
Apple, R ;
Park, L ;
Munoz, A ;
Saah, AJ ;
Goedert, JJ ;
Winkler, C ;
OBrien, SJ ;
Rinaldo, C ;
Detels, R ;
Blattner, W ;
Phair, J ;
Erlich, H ;
Mann, DL .
NATURE MEDICINE, 1996, 2 (04) :405-411
[9]   Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I peptide complex [J].
Kuroda, MJ ;
Schmitz, JE ;
Barouch, DH ;
Craiu, A ;
Allen, TM ;
Sette, A ;
Watkins, DI ;
Forman, MA ;
Letvin, NL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (09) :1373-1381
[10]   Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys [J].
Letvin, NL ;
Huang, Y ;
Chakrabarti, BK ;
Xu, L ;
Seaman, MS ;
Beaudry, K ;
Korioth-Schmitz, B ;
Yu, F ;
Rohne, D ;
Martin, KL ;
Miura, A ;
Kong, WP ;
Yang, ZY ;
Gelman, RS ;
Golubeva, OG ;
Montefiori, DC ;
Mascola, JR ;
Nabel, GJ .
JOURNAL OF VIROLOGY, 2004, 78 (14) :7490-7497